These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 22018047

  • 1. Favorable effects on metabolic risk factors with daily brewer's yeast in type 2 diabetic patients with hypercholesterolemia: a semi-experimental study.
    Khosravi-Boroujeni H, Rostami A, Ravanshad S, Esmaillzadeh A.
    J Diabetes; 2012 Jun; 4(2):153-8. PubMed ID: 22018047
    [Abstract] [Full Text] [Related]

  • 2. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 3. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes.
    Bahijiri SM, Mira SA, Mufti AM, Ajabnoor MA.
    Saudi Med J; 2000 Sep; 21(9):831-7. PubMed ID: 11376359
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 7. Oat-derived beta-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia.
    Reyna-Villasmil N, Bermúdez-Pirela V, Mengual-Moreno E, Arias N, Cano-Ponce C, Leal-Gonzalez E, Souki A, Inglett GE, Israili ZH, Hernández-Hernández R, Valasco M, Arraiz N.
    Am J Ther; 2007 Jul; 14(2):203-12. PubMed ID: 17414591
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia.
    Lukacsko P, Walters EJ, Cullen EI, Niecestro R, Friedhoff LT.
    Curr Med Res Opin; 2004 Jan; 20(1):13-8. PubMed ID: 14741066
    [Abstract] [Full Text] [Related]

  • 9. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H.
    Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y.
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [Abstract] [Full Text] [Related]

  • 14. [Lovastatin in the treatment of hypercholesterolemia in non-insulin-dependent diabetes mellitus patients].
    Zanella MT, Plavinik F, Zampieri M, Peres RB, Ribeiro AB.
    Arq Bras Cardiol; 1993 Jul; 61(1):27-31. PubMed ID: 8285861
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.
    Knopp RH, Tsunehara C, Retzlaff BM, Fish B, Nguyen H, Anderson S, Nguyen T.
    Metabolism; 2006 Dec; 55(12):1697-703. PubMed ID: 17142146
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
    Huang JC, Lee TY, Liou MJ, Lin CM, Pei D, Chen ZC, Liu RT, Kwok CF.
    Curr Med Res Opin; 2011 Aug; 27(8):1645-51. PubMed ID: 21699369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.